COMMUNIQUÉS West-GlobeNewswire

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
18/01/2024
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean [...]
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
18/01/2024
Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: [...]
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
18/01/2024
- The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis - The raise also includes a $450 million credit facility from Blue Owl [...]
MedBright AI Reaches US$100M in Total Clinic Revenue Under Contract with MedMatrix, the AI-Powered Data Analytics Platform
18/01/2024
VANCOUVER, British Columbia, Jan. 18, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright AI”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) has announced today that it has achieved its near term goal [...]
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
18/01/2024
WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio. On January 16, [...]
CENTOGENE Announces Preliminary Full Year 2023 Revenue
18/01/2024
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today [...]
Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck
18/01/2024
OBT, in collaboration with GORTEC, is evaluating OBT076, an innovative Antibody Drug Conjugate (ADC) targeting CD205 receptor that is highly overexpressed in solid and liquid tumors Oxford, UK, San Jose, Calif ., 18 [...]
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease
18/01/2024
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January , 2024 - Orphalan SA (“Orphalan” or “the Company”), an international [...]
Iktos announces the appointment of Avirup Bose as Chief Business Officer
18/01/2024
Iktos announces the appointment of Avirup Bose as Chief Business Officer Paris (France), 18 January, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the appointment of [...]
ONWARD® Announces Start of HemON NL Clinical Study
18/01/2024
HemON NL is evaluating the use of ARC-IM® Therapy to address hemodynamic instability after spinal cord injury EINDHOVEN, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the [...]
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
18/01/2024
Availability of VYVGART ® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx [...]
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
18/01/2024
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric [...]
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
18/01/2024
SHANGHAI, China, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Immatics Announces Pricing of $175 Million Public Offering
18/01/2024
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer [...]
Lowell Farms Inc. Announces Termination of the Zabala Road Lease
18/01/2024
SALINAS, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born cannabis company with advanced production capabilities including extraction, [...]
MedBright AI Investments Inc. Responds to OTC Markets Request on Recent Promotional Activity
18/01/2024
VANCOUVER, British Columbia, Jan. 17, 2024 (GLOBE NEWSWIRE) -- MEDBRIGHT AI INVESTMENTS INC. (CSE: MBAI; OTCQB: MBAIF; FSE: 1V7) (“ MedBright ” or the “ Company ”) announces that it has been requested by OTC Markets [...]
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
17/01/2024
Cytek’s Cutting-Edge Spectral Flow Cytometry Technology, Specialized Staff, Tools and Solutions Set New Benchmarks for Cell Analysis FREMONT, Calif. and BARCELONA, Spain, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Cytek [...]
StateHouse Announces Update to Board of Directors
17/01/2024
SAN DIEGO and TORONTO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc . (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically integrated cannabis company, today [...]
Sanofi: Information concerning the total number of voting rights and shares - December 2023
17/01/2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]

Pages